CBD and Kratom Together: What Research Shows and Doesn’t

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making health decisions based on this content.

By KratomCBDDirect.com Editorial Team | Last verified: August 2026

The Question: What Happens When CBD and Kratom Are Used Together?

Many consumers combine CBD and kratom for complementary effects, but virtually no clinical research directly examines what occurs when both are used concurrently. This article reviews what we know about each plant's biology separately, identifies theoretical interaction pathways, summarizes the sparse available evidence, and clarifies critical gaps that remain. Understanding this distinction—between what is studied versus what is assumed—is essential for safe decision-making.

The Mechanism: How CBD and Kratom Work in the Body

CBD's Pharmacological Profile

Cannabidiol (CBD) is a non-intoxicating phytocannabinoid that operates through multiple receptor systems. Its primary mechanisms include: (1) partial agonism at serotonin 5-HT1A receptors, implicated in mood regulation; (2) allosteric modulation of cannabinoid CB1 and CB2 receptors, affecting immune and pain signaling; (3) TRPV1 channel activation, involved in pain and inflammation; and (4) inhibition of fatty acid amide hydrolase (FAAH), an enzyme that breaks down endocannabinoids like anandamide. Additionally, CBD is metabolized primarily by cytochrome P450 3A4 and 2C19 enzymes in the liver.

Kratom's Pharmacological Profile

Kratom (Mitragyna speciosa) contains over 40 alkaloids, with mitragynine and 7-hydroxymitragynine as primary constituents. Mitragynine acts as a partial agonist at mu (μ) and delta (δ) opioid receptors at high doses, with additional activity at alpha-2 adrenergic receptors and monoamine receptors. This profile produces dose-dependent effects: stimulant at low doses (1–5 g), analgesic at moderate doses (5–10 g), and sedative at high doses (10+ g). Kratom alkaloids undergo hepatic metabolism involving multiple CYP450 enzymes, including 3A4 and 2D6.

Theoretical Interaction Pathways

Three interaction mechanisms are plausible but unstudied in humans: (1) Central nervous system (CNS) additive effects—both substances can depress CNS activity, particularly at higher doses, potentially increasing sedation, dizziness, or cognitive impairment; (2) Hepatic enzyme competition—both CBD and kratom alkaloids compete for metabolism via CYP3A4, potentially altering clearance rates and plasma concentrations of either compound; and (3) Receptor cross-talk—CBD's modulation of cannabinoid and serotonin systems may influence kratom's opioid-like and monoaminergic signaling, though the direction and clinical significance of such interaction is entirely unknown in humans.

Why These Pathways Matter

If CNS depression is additive, consumers might experience unexpected sedation or impaired motor function. If hepatic metabolism is competed, CBD or kratom levels could rise, potentially intensifying effects or side effects. However, these are hypothetical concerns grounded in pharmacology—not documented clinical outcomes. The absence of evidence is not evidence of safety.

Current Evidence: What Studies Actually Exist?

Human Clinical Trials on CBD + Kratom Combination

Finding: None published as of August 2026. A search of PubMed, Cochrane Library, and clinical trial registries (clinicaltrials.gov) reveals zero human studies specifically examining concurrent CBD and kratom use. This is the critical fact undergirding this entire article.

Mechanistic/In Vitro Studies

Limited bench research has examined CYP450 enzyme interactions. A 2019 study in Toxicology Reports found that CBD inhibits CYP3A4 and CYP2C19 in human hepatocyte cultures, suggesting potential for drug-drug interactions. Similarly, kratom alkaloids have been shown to compete for CYP3A4 metabolism in vitro, but no study has combined both substances in a single experimental model.

Individual-Substance Evidence (Separate Use)

CBD alone: Hundreds of studies document CBD's pharmacology, safety profile at doses up to 1500 mg/day, and interaction with certain medications (particularly those metabolized by CYP3A4). Adverse events are generally mild (fatigue, diarrhea, appetite changes) at typical doses (10–200 mg/day).

Kratom alone: Approximately 150 peer-reviewed studies and case reports exist. Research supports kratom's traditional use for pain and opioid withdrawal, but also documents dose-dependent risks including addiction potential, constipation, liver injury (rare, case-based), and seizures in vulnerable populations. Typical doses range 2–15 g daily.

Case Reports and Adverse Event Databases

No published case reports document adverse outcomes specifically from CBD + kratom combination use. However, the FDA's FAERS (Adverse Event Reporting System) and poison control centers have received individual reports of users combining these substances who experienced dizziness, sedation, or GI distress—though causality and whether the combination itself was responsible remain unestablished.

Evidence Table: Studies Relevant to CBD, Kratom, and Drug Metabolism

Practical Implications: What Should Consumers Know?

Current State: No Proven Benefit or Harm

Combining CBD and kratom is not prohibited by regulation, and many consumers report doing so without incident. However, the absence of adverse reports does not equal proof of safety—it reflects the lack of systematic monitoring, not the absence of risk. Consumers who choose to combine these substances should understand they are in a territory of minimal evidence.

Risk Scenarios to Consider

Scenario 1: Additive CNS depression. If using high-dose kratom (10–15 g) known for sedative effects plus CBD (100+ mg), drowsiness, dizziness, or impaired cognition may occur. Avoid driving or operating machinery.

Scenario 2: Medication interactions. If taking a drug metabolized by CYP3A4 (e.g., statins, antihistamines, blood pressure meds), combining that drug with both CBD and kratom could theoretically elevate drug levels. Discuss with your doctor or pharmacist.

Scenario 3: Pre-existing liver disease. Both substances undergo hepatic metabolism. In patients with liver impairment, clearance may be further reduced, increasing risk of accumulation and toxicity.

Practical Safety Recommendations

• Consult a healthcare provider familiar with both botanicals before combining them, especially if you take medications or have liver or kidney disease.
• Start with the lowest effective dose of each substance separately to establish baseline tolerance, then reassess before combining.
• Monitor for unexpected sedation, cognitive changes, nausea, or other new symptoms.
• Maintain a detailed log of doses, timing, and any effects—this data helps your healthcare provider assess causality if problems arise.
• Avoid combining high-dose kratom with high-dose CBD; if combining, use low-to-moderate doses of each.
• Be aware that kratom's quality is unregulated; alkaloid content varies widely. This makes predicting interactions even more uncertain.

Related Topics Worth Exploring

• CBD Drug Interactions: Comprehensive guide to CYP450 pathways and which medications may interact with CBD
• Kratom Pharmacology and Safety Profile: Deep dive into alkaloids, receptor activity, and documented adverse events

  This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

  Related reading: Mitragynine: Active Alkaloid in Kratom — What Research Shows | Kratom Alkaloid Opioid Receptor Binding: What Research Shows